99277-71-1

Basic information

• Product Name: 4-Bromo-2-nitrobenzoic acid
• Synonyms: 4-BROMO-2-NITROBENZOIC ACID;2-NITRO-4-BROMO BENZOIC ACID;4-Bromo-2-Nitrobenzoic Acid 2-Nitro-4-Bromobenzoic Acid;4-bromo-2-nitrobenzoic;Bromonitrobenzoicacid 42---;5-Bromo-2-carboxynitrobenzene;2-Bromo-2-nitrobenzoic acid
• CAS NO: 99277-71-1
• Molecular Formula: C₇H₄BrNO₄
• Molecular Weight: 246.01
• EINECS: 1312995-182-4
• Product Categories: blocks;Bromides;Carboxes;NitroCompounds;Multisubstituted Benzene;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;C7;Carbonyl Compounds;Carboxylic Acids;intermediate
• Mol File: 99277-71-1.mol

Chemical Properties

• Melting Point: 165-169 °C
• Boiling Point: 368.6 °C at 760 mmHg
• Flash Point: 176.7 °C
• Appearance: /
• Density: 1.892 g/cm³
• Vapor Pressure: 4.38E-06mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 1.97±0.25(Predicted)
• CAS DataBase Reference: 4-Bromo-2-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-2-nitrobenzoic acid(99277-71-1)
• EPA Substance Registry System: 4-Bromo-2-nitrobenzoic acid(99277-71-1)

Safety Data

• Hazard Codes: Xn,N,Xi
• Statements: 22-36/37/38-43-50
• Safety Statements: 26-36/37-61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 2
• HazardClass: IRRITANT
• PackingGroup: III
• Hazardous Substances Data: 99277-71-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-nitrobenzoic acid is used as an intermediate in the synthesis of Lonafarnib (L469445), a potential anticancer agent. It plays a crucial role in the development of this drug, which targets specific enzymes involved in cancer cell growth and proliferation.
Used in Organic Synthesis:
4-Bromo-2-nitrobenzoic acid is used as a reactant in Negishi-type coupling reactions with dimethylzinc in the presence of palladium-phosphine catalysis. This reaction allows for the formation of new carbon-carbon bonds, enabling the synthesis of a wide range of organic compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C7H4BrNO4/c8-4-1-2-5(7(10)11)6(3-4)9(12)13/h1-3H,(H,10,11)/p-1

Upstream product

• 875-51-4 4-Bromo-2-nitroaniline 
• 5551-12-2 4-bromo-2-nitrobenzaldehyde 
• 106-38-7 para-bromotoluene 
• 88-72-2 1-methyl-2-nitrobenzene 
• 610-36-6 4-amino-2-nitrobenzoic acid 
• 402948-06-5 3-(1H-benzoimidazol-2-yl)-4-hydroxy-1H-[1,7]naphthyridin-2-one 
• 60956-26-5 4-bromo-2-nitrotoluene 
• 79603-03-5 4-bromo-2-nitro-benzonitrile 

Downstream Products

• 27329-27-7 4-methyl-2-nitrobenzoic acid 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 99847-13-9 3-nitrobiphenyl-4-carboxylic acid 
• 158580-57-5 methyl 4-bromo-2-nitrobenzoate 
• 929192-93-8 4-bromo-2-nitro-N-(3-pyrrolidin-1-ylpropyl)benzamide 
• 22996-19-6 (4-bromo-2-nitrophenyl)methanol 
• 1356488-21-5 2-(4-bromo-2-nitrophenyl)-5-chlorothiophene 
• 1352637-93-4 3-nitrobiphenyl-4-carboxylic acid (3,4,5-trimethoxyphenyl)amide 
• 1352638-16-4 3-nitrobiphenyl-4-carboxylic acid (3,4-dihydroxy-5-methoxyphenyl)amide 
• 1393456-12-6 C₁₅H₁₀BrNO₂S 
• 1620682-51-0 1-allyl-4-bromo-2-nitrobenzene 
• 1620682-38-3 allyl 4-bromo-2-nitrobenzoate 
• 1644068-76-7 C₁₁H₈BrNO₃ 
• 29378-78-7 N,N-dimethyl-4-bromo-2-nitrobenzamide 

Relevant articles and documents

Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands

A novel strategy for the synthesis of cholecystokinin-2 receptor ligands was developed. The route employs a solution-phase synthesis of a series of anthranilic sulfonamides followed by a resin capture purification strategy to produce multi-milligram quant

Oxidation of 4-halo-2-nitrotoluene with tetrabutylammonium permanganate in pyridine: Development and safety evaluation

4-Halo-2-nitrobenzoic acids are synthesized by oxidation of 4-halo-2-nitrotoluene with tetrabutylammonium permanganate (TBAP) in pyridine in multigram quantities. A significant induction period is observed at room temperature, and the vigorous exothermic

Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists

A high throughput screening approach to the identification of selective cholecystokinin-2 receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, represented by 1-[2-[(2,1,3-benzothiadiazol-4- ylsulfonyl)amino]-5-chlorobenzoy

GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia,

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Quinazoline derivatives

A compound of the formula (I) or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.